Charles River on Muck Rack

Charles River

Weston
As seen in: Color Research & Application, PLOS ONE, WBZ-TV (Boston, MA), AU Investing, International Business Times (U.S.), Investing Canada, Investing.com, Investing.com UK, The Minnesota Star Tribune, Benzinga and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Charles

Contact Charles, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Advance your CGT drug development

|
By Charles River
| Cell & Gene Therapy Review Verified
From regulatory complexity to manufacturing hurdles to investor pressure, CGT drug developers face a uniquely demanding path to market. The 2026 Cell and Gene Therapy Summit, a premier one-day event in Boston on March 26, brings together over 170 industry leaders to tackle these challenges head-on. This year's agenda includes a keynote from Flagship Pioneering's CTO, patient advocacy, panels on drug development strategy and CGT investment, and a new poster session.
Open in Who Shared Issue with article?

Charles River at TD Cowen: Strategic Moves and Market Insights

|
By Charles River
| Investing.com
On Tuesday, March 3, 2026, Charles River Laboratories (NYSE:CRL) presented its strategic direction at the TD Cowen 46th Annual Health Care Conference. Incoming CEO Birgit Girshick outlined initiatives aimed at enhancing shareholder value, including acquisitions and divestitures, while addressing potential challenges such as FDA turnover and NIH funding cuts. The company’s stock has experienced a recent decline, prompting discussions of potential stock repurchases.
Open in Who Shared Issue with article?

Charles River and Gazi University partner on gene therapy research

|
By Charles River
| Investing.com
WILMINGTON, Mass. - Charles River Laboratories International, Inc. (NYSE:CRL), a $10.7 billion biotech services company whose shares have surged nearly 46% over the past six months, has formed a gene therapy collaboration with Gazi University Faculty of Medicine to provide plasmid DNA for AAV production and in vitro efficacy studies, according to a press release statement.
Open in Who Shared Issue with article?
See all 116 licensed articles (127 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified